{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:46:36Z","timestamp":1791913596974,"version":"4.3.4"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001170","name":"Cancer Council Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001755","name":"Mesothelioma Applied Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.lungcan.2021.11.006","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T12:04:29Z","timestamp":1637064269000},"page":"162-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Immune checkpoint inhibitor therapy for malignant pleural mesothelioma"],"prefix":"10.1016","volume":"162","author":[{"given":"Anna K","family":"Nowak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Loong","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Synat","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.lungcan.2021.11.006_b0005","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2021.11.006_b0010","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2021.11.006_b0015","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"10272","key":"10.1016\/j.lungcan.2021.11.006_b0020","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lungcan.2021.11.006_b0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/sonc.2002.30234","article-title":"New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents","volume":"29","author":"Nowak","year":"2002","journal-title":"Semin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2021.11.006_b0030","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11864-011-0149-1","article-title":"Novel targeted therapies and vaccination strategies for mesothelioma","volume":"12","author":"Bagia","year":"2011","journal-title":"Curr. Treat. Options Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2021.11.006_b0035","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.lungcan.2021.11.006_b0040","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2021.11.006_b0045","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabro","year":"2015","journal-title":"Lancet Respir. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2021.11.006_b0050","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2021.11.006_b0055","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2021.11.006_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma","author":"Quispel-Janssen","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2021.11.006_b0065","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.lungcan.2021.11.006_b0070","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/jjco\/hyaa069","article-title":"Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma","volume":"50","author":"Nakamura","year":"2020","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2021.11.006_b0075","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.lungcan.2021.11.006_b0080","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S2213-2600(20)30515-4","article-title":"Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study","volume":"9","author":"Yap","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2021.11.006_b0085","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9\u201315) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2021.11.006_b0090","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/1753465816628800","article-title":"Malignant pleural mesothelioma: an update on diagnosis and treatment options","volume":"10","author":"Kondola","year":"2016","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"10.1016\/j.lungcan.2021.11.006_b0095","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13063-018-2602-y","article-title":"CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial","volume":"19","author":"Fennell","year":"2018","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.lungcan.2021.11.006_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2021.01.323","article-title":"PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial","volume":"16","author":"Fennell","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"issue":"11","key":"10.1016\/j.lungcan.2021.11.006_b0105","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2021.11.006_b0110","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2021.11.006_b0115","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2021.11.006_b0120","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2021.11.006_b0125","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2021.11.006_b0130","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrd3500","article-title":"Cancer immunotherapy - revisited","volume":"10","author":"Lesterhuis","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.lungcan.2021.11.006_b0135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.cdd.4402255","article-title":"Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all","volume":"15","author":"van der Most","year":"2008","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.lungcan.2021.11.006_b0140","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/0008-5472.CAN-05-2967","article-title":"Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity","volume":"66","author":"van der Most","year":"2006","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.lungcan.2021.11.006_b0145","first-page":"4490","article-title":"Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors","volume":"63","author":"Nowak","year":"2003","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.lungcan.2021.11.006_b0150","first-page":"2353","article-title":"Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy","volume":"62","author":"Nowak","year":"2002","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2021.11.006_b0155","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.4049\/jimmunol.170.10.4905","article-title":"Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells","volume":"170","author":"Nowak","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.lungcan.2021.11.006_b0160","doi-asserted-by":"crossref","unstructured":"Lesterhuis, W.J., A.K. Nowak, and R.A. Lake, Immune stimulatory features of classical chemotherapy, in Cancer Immunotherapy - Immune Suppression and Tumor Growth, G.C. Prendergast and E.M. Jaffee, Editors. 2013 Academic Press.: London, UK. p. 395-416.","DOI":"10.1016\/B978-0-12-394296-8.00024-5"},{"issue":"23","key":"10.1016\/j.lungcan.2021.11.006_b0165","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMcibr061443","article-title":"A better way for a cancer cell to die","volume":"354","author":"Lake","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2021.11.006_b0170","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrc1613","article-title":"Immunotherapy and chemotherapy\u2013a practical partnership","volume":"5","author":"Lake","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2021.11.006_b0175","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1172\/JCI43656","article-title":"Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice","volume":"121","author":"Lesterhuis","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.lungcan.2021.11.006_b0180","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4161\/onci.1.2.18126","article-title":"STATing the importance of immune modulation by platinum chemotherapeutics","volume":"1","author":"Hato","year":"2012","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.lungcan.2021.11.006_b0185","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.lungcan.2021.11.006_b0190","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm.2028","article-title":"Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors","volume":"15","author":"Ghiringhelli","year":"2009","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2021.11.006_b0195","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2021.11.006_b0200","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI40269","article-title":"Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice","volume":"120","author":"Ramakrishnan","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.lungcan.2021.11.006_b0205","doi-asserted-by":"crossref","unstructured":"Hato, S.V., et al., Platinum-based cancer chemotherapeutics inhibit STAT signaling by blocking the SH2 domain. Cancer Research, 2013. 73(8 (Suppl)): p. Abstract nr. 2120.","DOI":"10.1158\/1538-7445.AM2013-2120"},{"issue":"4","key":"10.1016\/j.lungcan.2021.11.006_b0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061895","article-title":"Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity","volume":"8","author":"Lesterhuis","year":"2013","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.lungcan.2021.11.006_b0215","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1641390","article-title":"Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy\/checkpoint blockade combination treatment","volume":"8","author":"Aston","year":"2019","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.lungcan.2021.11.006_b0220","doi-asserted-by":"crossref","first-page":"956","DOI":"10.4049\/jimmunol.0900437","article-title":"Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma","volume":"185","author":"Anraku","year":"2010","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.lungcan.2021.11.006_b0225","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2021.11.006_b0230","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","author":"Forde","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.lungcan.2021.11.006_b0235","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003288","article-title":"JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma","volume":"9","author":"Miyamoto","year":"2021","journal-title":"J. ImmunoTher. Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2021.11.006_b0240","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1261241","article-title":"Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma","volume":"6","author":"Marcq","year":"2017","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.lungcan.2021.11.006_b0245","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","article-title":"Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors","volume":"4","author":"Awad","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"22","key":"10.1016\/j.lungcan.2021.11.006_b0250","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1002\/cncr.26143","article-title":"Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma","volume":"117","author":"Burt","year":"2011","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2021.11.006_b0255","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jtho.2016.06.022","article-title":"Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages","volume":"11","author":"Chene","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2021.11.006_b0260","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jtho.2016.06.021","article-title":"Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression","volume":"11","author":"Lievense","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2021.11.006_b0265","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","article-title":"Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression","volume":"189","author":"Kumar-Singh","year":"1999","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.lungcan.2021.11.006_b0270","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4161\/cbt.4.3.1644","article-title":"Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma","volume":"4","author":"DeLong","year":"2005","journal-title":"Cancer Biol. Ther."},{"issue":"7","key":"10.1016\/j.lungcan.2021.11.006_b0275","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7\u2013H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2021.11.006_b0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedres","year":"2015","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.lungcan.2021.11.006_b0285","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.lungcan.2021.11.006_b0290","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2019.02.001","article-title":"Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28\u20138 pharmDx assays","volume":"87","author":"Chapel","year":"2019","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.lungcan.2021.11.006_b0295","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.lungcan.2021.11.006_b0300","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.lungcan.2021.11.006_b0305","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","article-title":"Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma","volume":"14","author":"Mansfield","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2021.11.006_b0310","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.2017.417","article-title":"HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer","volume":"118","author":"Barnes","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2021.11.006_b0315","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/bjc.2017.269","article-title":"Evaluating the effect of immune cells on the outcome of patients with mesothelioma","volume":"117","author":"Chee","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2021.11.006_b0320","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.lungcan.2021.11.006_b0325","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.lungcan.2021.11.006_b0330","article-title":"Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI","volume":"3","author":"Lee","year":"2018","journal-title":"Insight"},{"issue":"3","key":"10.1016\/j.lungcan.2021.11.006_b0335","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.lungcan.2021.11.006_b0340","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3389\/fimmu.2020.00223","article-title":"Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy","volume":"11","author":"Zemek","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2021.11.006_b0345","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.587014","article-title":"Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses","volume":"11","author":"Kidman","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2021.11.006_b0350","doi-asserted-by":"crossref","DOI":"10.1177\/1177932219899051","article-title":"Multi-omics Data Integration, Interpretation, and Its Application","volume":"14","author":"Subramanian","year":"2020","journal-title":"Bioinf. Biol. Insights"},{"key":"10.1016\/j.lungcan.2021.11.006_b0355","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.csbj.2020.06.017","article-title":"Deep learning models in genomics; are we there yet?","volume":"18","author":"Koumakis","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221005997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221005997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:58:15Z","timestamp":1791910695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500221005997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":71,"alternative-id":["S0169500221005997"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.11.006","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor therapy for malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}